NCT07402343 2026-03-04
T-BRAIN
Maastricht University Medical Center
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07343479 2026-01-15
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07197008 2025-09-29
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07185958 2025-09-22
DART
Aalborg University Hospital
Not yet recruiting
NCT07034365 2025-06-29
Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer
Fudan University
Not yet recruiting
NCT06483672 2024-07-03
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06319950 2024-03-20
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Phase 2 Not yet recruiting
NCT06282874 2024-02-28
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Not yet recruiting